Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of “Moderate Buy” from Analysts

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $16.50.

A number of analysts have issued reports on NMRA shares. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, January 2nd. Bank of America lowered their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research report on Friday, February 14th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NMRA. Mirae Asset Global Investments Co. Ltd. bought a new position in Neumora Therapeutics during the fourth quarter worth $61,000. PNC Financial Services Group Inc. acquired a new position in Neumora Therapeutics during the fourth quarter worth $64,000. Quantbot Technologies LP acquired a new position in Neumora Therapeutics during the fourth quarter worth $92,000. PEAK6 LLC acquired a new position in Neumora Therapeutics during the fourth quarter worth $117,000. Finally, EntryPoint Capital LLC acquired a new position in Neumora Therapeutics during the fourth quarter worth $135,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Stock Performance

Shares of NMRA stock opened at $1.55 on Friday. The company has a market capitalization of $250.42 million, a price-to-earnings ratio of -0.83 and a beta of 2.54. The company has a 50-day simple moving average of $3.58 and a 200 day simple moving average of $9.05. Neumora Therapeutics has a 52 week low of $1.55 and a 52 week high of $21.00.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.